Evidence for whether GLP-1 receptor agonists can penetrate the BBB remains limited as it has been argued that brain capillary binding or sequestration may not have been accounted for [29]
He told The Associated Press a federal law permanently allowing the coverage is not essential right now but something for Congress to debate amongst themselves. We cant decide whats going to happen long term with Bridge until we see some of the data, he said, noting that other negotiations with drug companies to lower costs are ongoing
In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced nausea in 39% of participants
It may help to focus on making whole, unprocessed foods the majority of your diet and limiting those that are refined and high in sugar, Bannan adds
This data cannot be extrapolated to compounded versions
Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug